Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
SAB Biotherapeutics, Inc. (SABS) is the issuer whose common stock Woodline Partners LP reports beneficially owning 5,455,694 shares, or 5.7% of the class. The amount includes 1,180,694 common shares, 2,850,000 shares issuable upon conversion of Series B preferred stock underlying 28,500 Enrollment Warrants, and 1,425,000 shares issuable upon conversion of Series B preferred stock underlying 14,250 Data Release Warrants.
Woodline Partners is the investment adviser to Woodline Master Fund LP, which directly holds the securities and has the right to receive dividends or sale proceeds. The 5.7% calculation uses 90,986,368 common shares outstanding as of August 3, 2026, and assumes conversion of the preferred stock issuable upon exercise of the warrants. Woodline reports sole voting and dispositive power over the beneficially owned amount.
Key Figures
Beneficially owned:5,455,694 sharesReported ownership percentage:5.7%Common shares outstanding:90,986,368 shares+3 more
6 metrics
Beneficially owned5,455,694 sharesSAB Biotherapeutics common stock, including shares issuable upon conversion
Reported ownership percentage5.7%Calculated using 90,986,368 common shares outstanding as of August 3, 2026, and assuming conversion of preferred stock issuable upon warrant exercise
Common shares outstanding90,986,368 sharesAs of August 3, 2026
Common shares held1,180,694 sharesCommon shares included in Woodline Partners’ reported beneficial ownership
Shares issuable upon conversion—Enrollment Warrants2,850,000 sharesSeries B preferred stock underlying 28,500 Enrollment Warrants
Shares issuable upon conversion—Data Release Warrants1,425,000 sharesSeries B preferred stock underlying 14,250 Data Release Warrants
Key Terms
beneficially owned, Series B Preferred Stock, Enrollment Warrants, Data Release Warrants
4 terms
beneficially ownedfinancial
"Amount beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Series B Preferred Stockfinancial
"shares of Series B Preferred Stock"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Enrollment Warrantsfinancial
"underlying 28,500 Enrollment Warrants"
Data Release Warrantsfinancial
"underlying 14,250 Data Release Warrants"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many SABS shares does Woodline Partners report beneficially owning?
Woodline Partners LP reports beneficial ownership of 5,455,694 shares of SABS common stock, or 5.7% of the class.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
SAB Biotherapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
78397T202
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
78397T202
1
Names of Reporting Persons
Woodline Partners LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
5,455,694.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
5,455,694.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,455,694.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.7 %
12
Type of Reporting Person (See Instructions)
IA, PN
Comment for Type of Reporting Person: Consists of (i) 1,180,694 shares of Common Stock (as defined in Item 2(a)), (ii) 2,850,000 shares of Common Stock issuable upon conversion of 28,500 shares of Series B preferred stock (the "Series B Preferred Stock") underlying 28,500 enrollment warrants (the "Enrollment Warrants") and (iii) 1,425,000 shares of Common Stock issuable upon conversion of 14,250 shares of Series B Preferred Stock underlying 14,250 data release warrants (the "Data Release Warrants").
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
SAB Biotherapeutics, Inc.
(b)
Address of issuer's principal executive offices:
777 W 41st St, Suite 401, Miami Beach, Florida 33140
Item 2.
(a)
Name of person filing:
This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of SAB Biotherapeutics, Inc. (the "Company"), and shares of Common Stock issuable upon the conversion of Series B Preferred Stock issuable upon the exercise of the Data Release Warrants and Enrollment Warrants, directly held by the Woodline Fund.
The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
(c)
Citizenship:
Woodline Partners is a Delaware limited partnership.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
78397T202
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 90,986,368 shares of Common Stock outstanding as of August 3, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026, and assumes the conversion of the Series B Preferred Stock issuable upon the exercise of the Enrollment Warrants and the Data Release Warrants held by the Woodline Fund.
(b)
Percent of class:
5.7%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). The Woodline Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Woodline Partners LP
Signature:
/s/ Erin Mullen
Name/Title:
Erin Mullen, General Counsel & Chief Compliance Officer